ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO825

Beta-2 Microglobulin Levels and All-Cause Mortality: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Perl, Jeffrey, St. Michael's Hospital, Toronto, Ontario, Canada
  • Muenz, Daniel G., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Bieber, Brian, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Cases, Aleix, Hospital Clinic, Barcelona, Barcelona, Spain
  • Kanda, Eiichiro, Kawasaki Medical School, Kurashiki, OKAYAMA, Japan
  • Locatelli, Francesco, Azienda Socio Sanitaria Territoriale, Lecco, Italy
  • Morgenstern, Hal, University of Michigan, Ann Arbor, Michigan, United States
  • Port, Friedrich K., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Robinson, Bruce M., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Dialysis-related amyloidosis due to beta-2 microglobulin (β2M) accumulation among hemodialysis (HD) patients is now uncommon due to HD delivery improvements. The impact of β2M levels and other middle molecules on other adverse events among HD patients remains unclear. We sought to identify patient factors that may affect β2M level and estimate the effect of β2M on mortality.


Facilities in DOPPS phases 4-6 were included in this study if ≥50% of patients had β2M levels reported in ≥50% of follow-up rounds. Cox regression was used to estimate the association (hazard ratio [HR]; 95% CI) between β2M, categorized in tertiles, and all-cause mortality, adjusting for demographic factors, comorbidities, HD treatment factors, and stratified by study phase and region (Japan vs. Europe).


We identified 5366 patients from 77 HD facilities in Japan (n=3837), France, Italy, and Spain (n=1529). Median (IQR) values of β2M (mg/dL) were 2.58 (2.17-3.00) in Japan and 2.55 (1.98-3.21) in Europe. In cross-sectional, unadjusted analysis, patients in the upper β2M tertile had longer dialysis vintage, greater likelihood of urine volume <200mL/day, lower prevalence of diabetes, higher serum phosphorus, and higher C-reactive protein, relative to the lower β2M tertile. Little association was observed between β2M and HD treatment time. Compared with the lower β2M tertile, the adjusted HR for mortality was 1.20 (0.98-1.48, 95% CI) for the middle tertile and 1.44 (1.17-1.75, 95% CI) for the upper tertile (Figure).


β2M is positively associated with mortality, controlling for several potential confounders. Interventions targeting greater β2M clearance during HD therapy may be an effective therapeutic strategy to improve outcomes among these patients.


  • NIDDK Support